Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 430

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study

Emmett, Louise, Buteau, James, Papa, Nathan, Moon, Daniel, Thompson, James, Roberts, Matthew J., Rasiah, Kris, Pattison, David A., Yaxley, John, Thomas, Paul, Hutton, Anthony C., Agrawal, Shikha, Amin, Amer, Blazevski, Alexandar, Chalasani, Venu, Ho, Bao, Nguyen, Andrew, Liu, Victor, Lee, Jonathan, Sheehan-Dare, Gemma, Kooner, Raji, Coughlin, Geoff, Chan, Lyn, Cusick, Thomas, Namdarian, Benjamin, Kapoor, Jada, Alghazo, Omar, Woo, Henry H., Lawrentschuk, Nathan, Murphy, Declan, Hofman, Michael S., Stricker, Phillip·2021·European Urology

Abstract

BACKGROUND Multiparametric magnetic resonance imaging (MRI) is validated for the detection of clinically significant prostate cancer (csPCa), although patients with negative/equivocal MRI undergo biopsy for false negative concerns. In addition, 68Ga-PSMA-11 positron emission tomography/computed tomography (prostate-specific membrane antigen [PSMA]) may also identify csPCa accurately. OBJECTIVE This trial aimed to determine whether the combination of PSMA + MRI was superior to MRI in diagnostic performance for detecting csPCa. DESIGN, SETTING, AND PARTICIPANTS A prospective multicentre phase II imaging trial was conducted. A total of 296 men were enrolled with suspected prostate cancer, with no prior biopsy or MRI, recent MRI (6 mo), and planned transperineal biopsy based on clinical risk and MRI. In all, 291 men underwent MRI, pelvic-only PSMA, and systematic ± targeted biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Sensitivity, specificity, and predictive values (negative predictive value [NPV] and positive predictive value) for csPCa were determined for MRI, PSMA, and PSMA + MRI. PSMA + MRI was defined as negative for PSMA negative Prostate Imaging Reporting and Data System (PI-RADS) 2/3 and positive for either MRI PI-RADS 4/5 or PSMA positive PI-RADS 2/3; csPCa was any International Society of Urological Pathology (ISUP) grade group ≥2 malignancy. RESULTS AND LIMITATIONS Of the patients, 56% (n = 162) had csPCa; 67% had PI-RADS 3-5, 73% were PSMA positive, and 81% were combined PSMA + MRI positive. Combined PSMA + MRI improved NPV compared with MRI alone (91% vs 72%, test ratio = 1.27 [1.11-1.39], p < 0.001). Sensitivity also improved (97% vs 83%, p < 0.001); however, specificity was reduced (40% vs 53%, p = 0.011). Five csPCa cases were missed with PSMA + MRI (four ISUP 2 and one ISUP 3). Of all men, 19% (56/291) were PSMA + MRI negative (38% of PI-RADS 2/3) and could potentially have avoided biopsy, risking delayed csPCa detection in 3.1% men with csPCa (5/162) or 1.7% (5/291) overall. CONCLUSIONS PSMA + MRI improved NPV and sensitivity for csPCa in an MRI triaged population. Further randomised studies will determine whether biopsy can safely be omitted in men with a high clinical suspicion of csPCa but negative combined imaging. PATIENT SUMMARY The combination of magnetic resonance imaging (MRI) + prostate-specific membrane antigen positron emission tomography reduces false negatives for clinically significant prostate cancer (csPCa) compared with MRI, potentially allowing a reduction in the number of prostate biopsies required to diagnose csPCa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2021.08.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 430

Metadata

Authors
Emmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M. J., Rasiah, K., Pattison, D. A., Yaxley, J., Thomas, P., Hutton, A. C., Agrawal, S., Amin, A., Blazevski, A., Chalasani, V., Ho, B., Nguyen, A., Liu, V., Lee, J., Sheehan-Dare, G., Kooner, R., Coughlin, G., Chan, L., Cusick, T., Namdarian, B., Kapoor, J., Alghazo, O., Woo, H. H., Lawrentschuk, N., Murphy, D., Hofman, M. S., & Stricker, P.
Venue
European Urology
Publisher
Elsevier BV
Published
2021-12
Volume
80
Issue
6
Pages
682-689
ISSN
0302-2838 (ISSN-L)
OpenAlex
W3197467098
Cited by
430
References
3
FWCI
38.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. https://app.cochat.ai/papers/10.1016/j.eururo.2021.08.002
The paper
Emmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M. J., Rasiah, K., Pattison, D. A., Yaxley, J., Thomas, P., Hutton, A. C., Agrawal, S., Amin, A., Blazevski, A., Chalasani, V., Ho, B., Nguyen, A., Liu, V., Lee, J., . . . Stricker, P. (2021). The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology. https://doi.org/10.1016/j.eururo.2021.08.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.